RiskDex options gauge hits 93rd percentile in Mag 7 earnings signal

source:

[1] Obscure volatility measure points to a 'Magnificent Seven' earnings breakout (https://www.cnbc.com/2026/07/17/obscure-volat ...)[2] IShares Russell 1000 Growth: A Concentrated AI Bet That Is Lagging The S&P 500 (https://seekingalpha.com/article/4922628-isha ...)[3] Has the AI Rally Made S&P 500 ETFs Too Risky? What Investors Need to Know (https://www.msn.com/en-us/money/top-stocks/ha ...)[4] AMZN Amazon.com, Inc. (https://seekingalpha.com/symbol/AMZN/news ...)

Related News

Jul 18 2026, 14:10

Viking Therapeutics dips as Wall Street sees 150% upside on VK2735

Viking Therapeutics shares have pulled back from June highs, with Wall Street maintaining a consensus price target of $91, implying 150% upside from current levels, according to Visible Alpha. "The excitement stems from VK2735 and its potential in the highly lucrative weight-loss market," analysts at Visible Alpha said, citing the drug's dual formulation as a key differentiator. The stock rose more than 19% in June before retreating. The San Diego-based biotech is developing VK2735 as both a subcutaneous injection and an oral tablet, allowing patients to start with injections and transition to oral maintenance. Phase 2 data showed VK2735 produced a steeper velocity of weight loss compared with rival GLP-1 and GIP therapies from Novo Nordisk and Eli Lilly. The subcutaneous phase 3 trial is underway, with results expected no earlier than late 2027. The oral phase 3 trial is scheduled to begin in the fourth quarter of 2026, with data due in 2028. A phase 1 maintenance dosing trial is also in progress, where participants receive subcutaneous VK2735 for 19 weeks before switching to various maintenance doses. Results from the subcutaneous period are due in the current quarter, while oral maintenance data are expected in the first half of 2027. Risks remain. The phase 2 oral trial showed questionable tolerability data, and the long wait for phase 3 results leaves the stock exposed to binary trial risk. The phase 1 maintenance results over the next six months will provide the earliest read on whether VK2735 can sustain weight loss after the initial treatment period. The current dip offers an entry point ahead of those data, but the multi-year timeline to phase 3 readouts means investors face a prolonged period of uncertainty. The maintenance trial results due in the coming quarters will be the first meaningful signal on whether VK2735 can deliver the durability that the obesity market demands. This article is for informational purposes only and does not constitute investment advice.

Jul 18 2026, 14:08

AIPI's 36.5% weekly yield masks a 12-point lag to QQQ

**The REX AI Equity Premium Income ETF pays $13.75 a year per share in weekly distributions, but its covered-call strategy has capped total return at 15% over the past 12 months — roughly half the gain of the plain-vanilla Nasdaq-100.** A 36.5% distribution yield paid in weekly slices pulls income investors toward the REX AI Equity Premium Income ETF (NASDAQ:AIPI). The fund packages exposure to major artificial intelligence names with a covered-call overlay that distributes cash every seven days. The problem is that a distribution rate is not a return, and once the two are separated, AIPI starts to look like a fund quietly financing part of its own payout. "The current rangebound AI market is ideal for aggressive call writing, but a significant portion of these payouts may be a return of capital," said Cain Lee, an analyst at Seeking Alpha. "If AI stock volatility decreases or the sector experiences a sharp decline, the sustainability of the yield comes into question." Over the past year, AIPI returned 15% on price, while the Invesco QQQ Trust (NASDAQ:QQQ), which tracks the Nasdaq-100 and holds most of the same AI names, returned 27%. Year-to-date, the gap widens further: AIPI is up 5% against QQQ's 15%. That roughly 12-percentage-point delta is the covered call in action. When NVIDIA rips through a strike price, AIPI's call writer hands the upside to the option buyer and collects premium instead. In a bull run for AI, capped upside is the entire story. The stakes are straightforward for the $414 million fund. AIPI owns a basket of AI-linked equities — top positions include Palantir (NASDAQ:PLTR), CrowdStrike (NASDAQ:CRWD), NVIDIA (NASDAQ:NVDA), Datadog (NASDAQ:DDOG) and ARM (NASDAQ:ARM) — split roughly 40% into "Purity Leaders" with direct AI revenue and 60% into "Key Enablers" in infrastructure and services. The manager sells slightly out-of-the-money call options on those names to harvest premium. That premium, plus return of capital, funds the distributions. In May 2026, the fund shifted from monthly checks to weekly ones, landing between $0.243583 and $0.263988 per share. Same money, more frequent envelopes. ## The Yield That Eats Its Own Principal Distributions on top of a share price that drifts sideways create an optical illusion. The trailing 12-month distribution of $13.75 per share on a roughly $35 stock is real cash. But if a chunk of it is a return of capital, as multiple analysts have argued, the fund is partly refunding your own money and calling it yield. The Pluang analysis from earlier this month warned that "a significant portion of these payouts may be a return of capital, raising concerns about the long-term sustainability if AI stock volatility decreases or the sector experiences a sharp decline." Covered-call income funds shine in one specific regime: sideways chop. When AI stocks trade in a range, option premiums are fat, calls expire worthless, and the fund keeps both the premium and the shares. Roberts Berzins framed the downside case just as cleanly, noting that "a significant L-shaped sell-off in the AI sector poses the primary risk to both its income generation and Net Asset Value." Sharp rally hurts you. Sharp crash hurts you more. Grinding sideways is the sweet spot. ## Who the Fund Fits The investor AIPI fits is specific. Retirees or income-focused holders who want a small tactical AI sleeve — 3% to 7% of a diversified portfolio — who genuinely need weekly or monthly cash flow, and who track total return rather than the distribution headline. The 0.65% expense ratio on an actively managed AI sleeve is not cheap, and the portfolio leans hard on a narrow set of volatile names. If you are buying AIPI because you want to own the AI boom, you are in the wrong fund. QQQ has already handed you nearly double the return over the past year, without the return-of-capital accounting, without capped upside, and at a fraction of the expense. The 36.5% yield is real. What matters is what is left of your share price when the checks stop being novel. This article is for informational purposes only and does not constitute investment advice.

Jul 18 2026, 14:06

Strait of Hormuz blockade reshapes global energy flows as buffers dwindle

Iran's control of the Strait of Hormuz since late February has blocked a waterway that normally carries one-fifth of the world's oil and gas, forcing a fundamental reshaping of global energy trade routes. "The buffers that have kept markets stable — strategic reserves, alternative pipelines, and lower Chinese demand — are running thin," said Fatih Birol, executive director of the International Energy Agency. "We should be worried if the situation does not improve in the next few weeks." Brent crude surged to nearly $126 a barrel in late April before easing after a coordinated IEA release of as much as 400 million barrels knocked about $20 off prices. US gasoline averaged $3.94 a gallon Thursday, up from $2.98 on Feb. 26, according to AAA data. Just 13 vessels transited the strait on Wednesday, compared with 138 a day before the conflict, according to Kpler. The disruption has hit Asia hardest — the region sourced 80% to 90% of its energy imports through the strait — with developing economies including Pakistan, Bangladesh and India bearing the brunt. The IEA's 400-million-barrel release, while the largest in history, consumed only 20% of member countries' strategic stocks, Birol said, warning that the remaining 80% offers limited insulation if the blockade persists. **Alternative Routes Face Their Own Risks** Saudi Arabia has rerouted some crude volumes through a pipeline to the Red Sea, boosting exports via the Bab el-Mandeb Strait. Crude and condensate transiting that waterway rose to 5.4 million barrels a day in the first quarter of 2026, up from 3.7 million in the same period a year earlier, according to the US Energy Information Administration. Liquefied natural gas flows through the passage resumed at 2.9 billion cubic feet a day after halting entirely in mid-2025. But the Bab el-Mandeb carries its own threat. Iran's Islamic Revolutionary Guard Corps has warned it could target "all other export corridors that benefit the US and its allies," and Houthi officials in Yemen have threatened to close both straits in an operational alliance. During the Houthi campaign against Red Sea shipping in 2023 and 2024, transit through the Bab el-Mandeb fell by more than half and shipping costs soared. **Strategic Stocks Are Not Infinite** China entered the conflict with more than 1 billion barrels of crude in storage, and its shift toward electric vehicles and public transport has curbed demand growth. US production has risen by 1 million to 2 million barrels a day. Neither buffer is sustainable. "The US increased 1 million, 2 million but it cannot increase 10 million," Birol said. The IEA's coordinated release in March signaled that member countries could tap reserves again if conditions worsen. "Even though it was huge, it was only 20% of the stocks we have," Birol said. "Eighty percent is still in the pocket." The longer the strait remains blocked, the more the world's emergency cushion erodes — and the fewer tools remain to absorb the next shock. President Trump's suggestion last week that the US could control the strait and collect tolls, which he quickly walked back, did little to reassure markets already pricing in a prolonged disruption. *This article is for informational purposes only and does not constitute investment advice.*